2018
DOI: 10.1007/s12253-018-0510-9
|View full text |Cite
|
Sign up to set email alerts
|

Sarcomas of the Oral and Maxillofacial Region: Analysis of 26 Cases with Emphasis on Diagnostic Challenges

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
19
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(19 citation statements)
references
References 49 publications
0
19
0
Order By: Relevance
“…Multimodal therapy has been used in the treatment of RMS, and these treatments contribute to locoregional control (LCR) of the disease, especially in those where the surgical approach is restricted due to the extension and impairment of anatomic structures [ 1 , 3 ]. In this case report, a favorable clinical response to LCR was shown, based on neoadjuvant QT+ followed by concomitant RT+.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Multimodal therapy has been used in the treatment of RMS, and these treatments contribute to locoregional control (LCR) of the disease, especially in those where the surgical approach is restricted due to the extension and impairment of anatomic structures [ 1 , 3 ]. In this case report, a favorable clinical response to LCR was shown, based on neoadjuvant QT+ followed by concomitant RT+.…”
Section: Discussionmentioning
confidence: 99%
“…Sarcomas of the Head and Neck (SHN) are defined as malignant neoplasms derived from mesenchymal cells, whose origin is from bone, cartilage, muscle, vascular, adipose, and neurogenic tissues, with rapid growth, aggressive and infiltrative behavior, and the capacity for high locoregional recurrence [ 1 , 2 ].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…They comprise of < 1% of adult malignancies and 15-20% of pediatric malignancies [3][4]. Maxillofacial sarcomas comprise 5-10% of all sarcoma cases [5][6][7][8][9][10][11][12] and < 1% of all malignant maxillofacial tumors [5,10,[13][14][15][16]. Over 70 subtypes of sarcomas were desribed so far [3,17].…”
Section: Epidemiologymentioning
confidence: 99%